Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands), 09 January 2026 – 5:40 PM CET
Disclosure of notification received from BNP Paribas
Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification from BNP Paribas Asset Management Holding.
Notification by BNP Paribas Asset Management Holding
Further information
Ignacio Artola
Global Investor Relations Leader
investors@fagron.com
About Fagron
Fagron is the leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 35 countries around the world.
The Belgian company Fagron NV is based on Venecoweg 20A in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron ’s operational activities are managed through the Dutch company Fagron BV. Fagron BV’s head office is located in Rotterdam.
Important information regarding forward-looking statements
Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.
In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.
Attachment